Clinical Trial Update: Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and efficacy of IV CXA-101 plus IV ceftazidime for complicated urinary tract infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection

Drugs mentioned

• CXA-101 (IV) (CXA-101)
• Ceftazidime (IV) (ceftazidime)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Complicated Urinary Tract Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-15